Equities analysts predict that Viewray Inc (NASDAQ:VRAY) will announce earnings of ($0.22) per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Viewray’s earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.23). Viewray posted earnings per share of ($0.26) in the same quarter last year, which indicates a positive year over year growth rate of 15.4%. The company is scheduled to announce its next quarterly earnings results on Monday, November 12th.
On average, analysts expect that Viewray will report full-year earnings of ($0.75) per share for the current fiscal year, with EPS estimates ranging from ($0.84) to ($0.67). For the next fiscal year, analysts forecast that the company will post earnings of ($0.49) per share, with EPS estimates ranging from ($0.67) to ($0.35). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Viewray.
Viewray (NASDAQ:VRAY) last issued its quarterly earnings data on Friday, August 3rd. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.09). Viewray had a negative return on equity of 353.05% and a negative net margin of 83.84%. The business had revenue of $16.44 million during the quarter, compared to analyst estimates of $15.97 million. During the same quarter last year, the firm earned ($0.15) EPS. Viewray’s revenue for the quarter was up 2255.3% compared to the same quarter last year.
Viewray traded up $0.10, hitting $9.89, during midday trading on Friday, Marketbeat reports. The company’s stock had a trading volume of 1,857,253 shares, compared to its average volume of 2,070,624. Viewray has a 1-year low of $5.11 and a 1-year high of $13.21. The company has a current ratio of 3.33, a quick ratio of 3.04 and a debt-to-equity ratio of 1.17.
In other news, insider Fmr Llc sold 295,850 shares of the business’s stock in a transaction that occurred on Thursday, July 26th. The shares were sold at an average price of $12.08, for a total value of $3,573,868.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Orbimed Advisors Llc sold 1,368,796 shares of the business’s stock in a transaction that occurred on Friday, August 10th. The shares were sold at an average price of $9.97, for a total transaction of $13,646,896.12. The disclosure for this sale can be found here. Insiders sold a total of 2,728,941 shares of company stock valued at $29,286,786 over the last 90 days. Corporate insiders own 43.93% of the company’s stock.
Large investors have recently modified their holdings of the company. Artisan Partners Limited Partnership bought a new stake in shares of Viewray during the 2nd quarter valued at approximately $6,852,000. FMR LLC grew its holdings in shares of Viewray by 36.9% during the 2nd quarter. FMR LLC now owns 7,670,767 shares of the company’s stock valued at $53,082,000 after purchasing an additional 2,069,086 shares during the last quarter. Cortina Asset Management LLC bought a new stake in shares of Viewray during the 2nd quarter valued at approximately $4,186,000. BlackRock Inc. grew its holdings in shares of Viewray by 59.3% during the 2nd quarter. BlackRock Inc. now owns 2,962,937 shares of the company’s stock valued at $20,503,000 after purchasing an additional 1,102,991 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC grew its holdings in shares of Viewray by 31.2% during the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 84,100 shares of the company’s stock valued at $582,000 after purchasing an additional 20,000 shares during the last quarter. Institutional investors own 84.02% of the company’s stock.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Further Reading: Growth Stocks, What They Are, What They Are Not
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.